Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Appointed director
Quarterly results
Director departure
ACHILLION PHARMACEUTICALS INC (ACHN) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/07/2019 8-K Quarterly results
Docs: "N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, Par Value $0.001 per share ACHN Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined i...",
"Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update"
08/08/2019 8-K Quarterly results
Docs: "FORM 8-K",
"Achillion Reports Second Quarter 2019 Financial Results and Provides Corporate Update"
05/09/2019 8-K Quarterly results
Docs: "Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected ...",
"Achillion Reports First Quarter 2019 Financial Results"
03/07/2019 8-K Quarterly results
Docs: "FORM 8-K",
"Achillion Reports Fourth Quarter and Full Year 2018 Financial Results"
11/07/2018 8-K Quarterly results
Docs: "SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 7, 2018 Achillion Pharmaceuticals, Inc. Delaware 001-33095 52-2113479 300 George Street New Haven, CT 06511 Registrant's telephone number, including area code: 624-7000 N/A Check the appropriate box if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act . ☐ Pre-commencement communications pursuant to Rule 14a-2 under the Exchange Act )",
"ACHILLION REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS"
08/08/2018 8-K Quarterly results
Docs: "FORM 8-K",
"ACHILLION REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS"
05/02/2018 8-K Quarterly results
Docs: "FORM 8-K",
"ACHILLION REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND MANAGEMENT TRANSITION"
02/22/2018 8-K Quarterly results
Docs: "ACHILLION ANNOUNCES RESTRUCTURING TO ADVANCE CORPORATE STRATEGY; ANNOUNCES 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS"
11/01/2017 8-K Quarterly results
Docs: "FORM 8-K",
"ACHILLION REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL PROGRAMS"
08/08/2017 8-K Quarterly results
Docs: "FORM 8-K",
"ACHILLION REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS AND PROOF-OF-CONCEPT WITH A FIRST-IN-CLASS, ORAL FACTOR D INHIBITOR"
05/04/2017 8-K Form 8-K - Current report
02/23/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
08/04/2016 8-K Form 8-K - Current report
05/03/2016 8-K Quarterly results
Docs: "ACHILLION REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL PROGRAMS"
02/25/2016 8-K Quarterly results
Docs: "ACHILLION REPORTS 2015 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS"
11/05/2015 8-K Quarterly results
Docs: "ACHILLION REPORTS THIRD QUARTER AND NINE MONTH 2015 FINANCIAL RESULTS"
08/10/2015 8-K Quarterly results
Docs: "ACHILLION REPORTS SECOND QUARTER AND SIX MONTH 2015 FINANCIAL RESULTS"
05/07/2015 8-K Quarterly results
Docs: "ACHILLION REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS"
03/05/2015 8-K Quarterly results
Docs: "ACHILLION REPORTS 2014 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS"
11/04/2014 8-K Quarterly results
Docs: "ACHILLION REPORTS THIRD QUARTER AND NINE MONTH 2014 FINANCIAL RESULTS"
08/07/2014 8-K Quarterly results
Docs: "ACHILLION REPORTS SECOND QUARTER AND SIX MONTH 2014 FINANCIAL RESULTS"
03/07/2014 8-K Quarterly results
Docs: "ACHILLION REPORTS 2013 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS"
11/12/2013 8-K Form 8-K - Current report
08/07/2013 8-K Form 8-K - Current report
02/20/2013 8-K Quarterly results
Docs: "ACHILLION REPORTS 2012 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS"
11/08/2012 8-K Form 8-K - Current report
08/08/2012 8-K Form 8-K - Current report
05/09/2012 8-K Quarterly results
Docs: "ACHILLION REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS"
11/08/2011 8-K Form 8-K - Current report
08/09/2011 8-K Form 8-K - Current report
05/04/2011 8-K Form 8-K - Current report
10/28/2010 8-K Form 8-K - Current report
08/13/2010 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy